What will be the CDC-reported 12-month rolling total of U.S. synthetic opioid overdose deaths (ICD-10 code T40.4, synthetic opioids excluding methadone, primarily fentanyl-driven) for the 12-month period ending December 2027?

The 12-month rolling total for synthetic opioid deaths (T40.4) has collapsed from a mid-2023 peak of roughly 78,300 to a predicted 35,115 by April 2026 44 sources. Calendar year 2025 closed at roughly 38,500 predicted deaths 2 sources. The year-over-year decline for the period ending April 2026 was approximately 20% data.cdc.gov, maintaining a steep downward trajectory driven by broad drops in overall overdose fatalities 2 sources.

Breaking down the early 2026 data shows that deaths in January through April ran about 850 per month below the same period in 2025. This puts the annualized run rate in early 2026 roughly around 30,000 to 33,000. Assuming the 2026 total lands near 31,000, the median estimate of 28,430 anticipates that the steep 20–35% annual declines of the past two years will decelerate to a more sustainable 8–10% drop in 2027. This base case also accounts for the standard 1–2% upward revision typical of initial provisional reporting congress.gov.

There are already localized signs that the decline is slowing; for instance, suspected-overdose ED visits for the 12 months ending March 2026 fell by only 2.6% year-over-year ophthalmologyadvisor.com. However, mid-2026 state-level data—such as a 9.5% continuing decline in Maine and the fading of Washington state's late-2025 rebound—confirm the overall downward trend remains intact for now 2 sources. If the current rapid 15–20% annual pace of decline unexpectedly persists through 2027 without plateauing, the total could fall near the 10th percentile estimate of 21,670.

The upper tail, extending to roughly 38,300, reflects the fragility of the current decline, the exact mechanics of which remain only partly understood brookings.edu. A major driver appears to be lower fentanyl purity tied to international precursor chemical restrictions 2 sources. This creates significant reversal risk if illicit suppliers adapt via new precursor routes or shift to highly potent substitutes like nitazenes or carfentanil 3 sources. Furthermore, recent policy changes—including restrictions on federal funds for drug-testing strips and potential Medicaid cuts—could severely threaten access to naloxone and addiction treatment commonwealthfund.org, opening the door to a plateau or moderate rebound by 2027.